The federal agency’s OK came with a warning about limiting the drug’s use as antibiotic drug resistance grows around the globe.
Revarbio contains two previously approved antibiotics, imipenem and cilastatin, as well as relebactam, a new beta-lactamase inhibitor. It is an injection.
While the FDA approval comes as a win for antibiotic drug development, the FDA warned that to maintain the efficacy of the therapy, the drug must only be used to treat infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria.
“The FDA remains focused on facilitating the development of safe and effective new antibacterial drugs to give patients more options to fight serious infections,” said Ed Cox, MD, director of the Office of Antimicrobial Products at the FDA. “It is important that the use of Recarbrio be reserved for situations when there are limited or no alternative antibacterial drugs for treating a patient’s infection.”
Read the news release here.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
New Jersey physician, pharmacy workers charged in $10M kickback scheme
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.